Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives Average Recommendation of “Buy” from Analysts

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has received a consensus rating of “Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $36.60.

KNSA has been the topic of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th. Evercore ISI raised their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. boosted their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock opened at $18.54 on Thursday. The company has a market cap of $1.34 billion, a PE ratio of -132.42 and a beta of 0.29. The firm has a fifty day moving average price of $20.58 and a two-hundred day moving average price of $23.27. Kiniksa Pharmaceuticals has a fifty-two week low of $16.56 and a fifty-two week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. During the same quarter in the prior year, the company posted ($0.20) EPS. The company’s quarterly revenue was up 67.4% compared to the same quarter last year. Analysts expect that Kiniksa Pharmaceuticals will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the transaction, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 14,000 shares of the stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the completion of the sale, the chief operating officer now owns 88,975 shares of the company’s stock, valued at $1,622,904. This trade represents a 13.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,092 shares of company stock worth $471,609 in the last three months. Insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth $50,000. CWM LLC boosted its stake in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. nVerses Capital LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the 3rd quarter valued at about $80,000. Lynx1 Capital Management LP bought a new stake in shares of Kiniksa Pharmaceuticals in the second quarter valued at about $177,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth about $189,000. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.